ONC Share Price

Open 0.85 Change Price %
High 0.87 1 Day -0.08 -9.20
Low 0.77 1 Week -0.17 -17.71
Close 0.79 1 Month 0.19 31.67
Volume 411403 1 Year 0.19 31.67
52 Week High 1.13
52 Week Low 0.19
ONC Important Levels
Resistance 2 0.88
Resistance 1 0.84
Pivot 0.81
Support 1 0.74
Support 2 0.70
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
RY 93.47 -0.20%
RY 93.47 -0.20%
BBD-B 2.11 -4.09%
NSU 3.03 -2.88%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
IMP 0.10 25.00%
IMP 0.10 25.00%
IMP 0.10 25.00%
AVP 0.07 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
ANX 0.06 -14.29%
ANX 0.06 -14.29%
CTU-A 0.19 -9.52%
ONC 0.79 -9.20%
ONC 0.79 -9.20%
CCO 13.09 -8.33%
CCO 13.09 -8.33%
CCO 13.09 -8.33%
SLR 1.02 -7.27%
More..

Oncolytics Biotech Inc (TSE: ONC)

ONC Technical Analysis 3
As on 28th Apr 2017 ONC Share Price closed @ 0.79 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.41 & Buy for SHORT-TERM with Stoploss of 0.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
ONC Target for May
1st Target up-side 1.05
2nd Target up-side 1.23
3rd Target up-side 1.41
1st Target down-side 0.53
2nd Target down-side 0.35
3rd Target down-side 0.17
ONC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncolyticsbiotech.com
ONC Address
ONC
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada
Phone: 403-670-7377
Fax: 403-283-0858
Interactive Technical Analysis Chart Oncolytics Biotech Inc ( ONC TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oncolytics Biotech Inc
ONC Business Profile
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.